Here we show that for immune evasive tumours, this can be achieved with additional targeting of SHP2 and that it is the combination of both the tumour cell-intrinsic and cell-extrinsic effects of SHP2 inhibition that sensitises tumours to ICB and generates durable responses. The gene discussed is PTPN11; the disease is neoplasm.